November 15, 2013
1 min read
Save

Avedro begins two new cross-linking trials in US

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Avedro announced that the first patients have been treated in two U.S. Food and Drug Administration clinical trials, according to a press release.

LASIK with cross-linking (LASIK Xtra) is a 2-minute procedure to investigate if cross-linking after LASIK reduces regression of refractive outcome in patients with hyperopia or hyperopic astigmatism, the release said.

Pulse accelerated cross-linking investigates pulsed UVA light to treat keratoconus, according to the release. Avedro’s KXL system allows for pulsed UVA light, which is important for higher-power accelerated cross-linking.
The KXL system is available internationally. No Avedro products have been approved for use in the U.S.